Pharma's Post-Pandemic Story To Unlock A Cancer-Free Era
Pharma's Post-Pandemic Story To Unlock A Cancer-Free Era
制药公司的后疫情故事将开启无癌时代
Pfizer (NYSE:PFE) and Moderna (NASDAQ:MRNA) did not only earn billions of dollars from their COVID-19 leading products but also rose to fame for saving the world from an unforeseen pandemic. But, in a post-pandemic world, Pfizer and Moderna shares lost about 30% of their respective value over the past year. Yet, these struggling pharma companies are promising to turn the tide with their new long-term focus on oncology. Moreover, smaller companies like Mainz Biomed N.V. (NASDAQ:MYNZ) already broke ground when it comes to revolutionizing cancer treatment.
辉瑞（纽约证券交易所代码：PFE）和摩德纳（纳斯达克股票代码：MRNA）不仅从其 COVID-19 领先产品中获得了数十亿美元的收入，而且还因拯救世界免受不可预见的疫情而声名鹊起。但是，在大流行后的世界中，辉瑞和Moderna的股票在过去一年中分别下跌了约30％。然而，这些陷入困境的制药公司承诺通过将新的长期重点放在肿瘤学上来扭转局面。此外，像美因兹生物医学公司（纳斯达克股票代码：MYNZ）这样的小型公司在彻底改变癌症治疗方面已经破土动工。
Pfizer might be down, but it is certainly not...
辉瑞可能会倒闭，但...
登录免费看全文
登录/注册